Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Osteoporosis drugs linked to lower Alzheimer's disease and dementia risk | Fox News (opens in a new tab)

foxnews.com · 2025-11-17

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 4 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredAll adults in the Hong Kong study had recently been diagnosed with osteoporosis or had suffered a serious fracture, and none had previously taken osteoporosis medication.View evidenceHide evidence

Why this verdict

The abstract profile supports that participants were adults aged 60+ in Hong Kong with osteoporosis or fragility fracture, but it does not verify that the diagnosis/fracture was recent, that the fracture was 'serious' rather than fragility-related, or that none had previously taken osteoporosis medication. These details may depend on full methods not available at abstract depth.

1

Study evidence

In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)

“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
Claim 2 of 6Not coveredThe authors said the results may not generalize beyond the Chinese population studied and noted limitations including lack of baseline cognitive testing and missing information on osteoporosis severity, fractures, calcium/vitamin D use, and other external factors.View evidenceHide evidence

Why this verdict

The abstract profile establishes that the data came from Hong Kong, but it does not include the stated author limitations about generalizability beyond the Chinese population, lack of baseline cognitive testing, osteoporosis or fracture severity, calcium/vitamin D use, or other external factors. Those limitation details are not verifiable from the supplied abstract-depth profile.

1

Study evidence

In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)

“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
Claim 3 of 6SupportedCommonly used osteoporosis drugs were linked to a lower risk of Alzheimer’s disease and other types of dementia in a large study of older adults.View evidenceHide evidence

Why this verdict

The paper profile supports an associational finding in a large Hong Kong observational cohort of adults aged 60+ with osteoporosis or fragility fracture: nitrogen-containing bisphosphonate use was associated with lower ADRD incidence. The headline wording is framed as 'linked,' not proven causal, so it does not outrun the abstract-level evidence.

1

Study evidence

In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)

“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
Claim 4 of 6SupportedAmong 121,492 adults age 60 or older, use of nitrogen-containing bisphosphonates was associated with a 16% lower risk of developing Alzheimer’s disease and related dementias compared with people who did not take osteoporosis medications.View evidenceHide evidence

As stated16% lower risk

Why this verdict

The abstract profile reports an overall sample of 121,492 patients and an NBP-vs-untreated hazard ratio of 0.84 for ADRD, corresponding to a 16% lower hazard/risk as commonly stated. The story’s comparator description, people who did not take osteoporosis medications, matches the untreated comparator at this depth.

1

Study evidence

In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)

“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
Claim 5 of 6SupportedThe risk was 24% lower compared with people taking other types of osteoporosis medications.View evidenceHide evidence

As stated24% lower

Why this verdict

The paper profile reports NBP use versus non-NBP anti-osteoporosis medication users with HR 0.76, which corresponds to a 24% lower hazard/risk. The claim is associational and matches the abstract-level result.

1

Study evidence

In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)

“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
Claim 6 of 6SupportedThe study was observational in design, so the findings do not prove that bisphosphonate use reduces dementia risk.View evidenceHide evidence

Why this verdict

The paper profile identifies the study as retrospective observational human research, so the story’s caveat that the findings do not prove bisphosphonate use reduces dementia risk is warranted. The abstract-level profile says the authors recommend further studies; the more specific quoted wording about confirmation in a clinical trial is not independently verifiable from the abstract profile alone, but the central no-causation caveat is supported.

1

Study evidence

In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)

“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Analytic methods: 1:1 time-dependent propensity score matching and Cox proportional hazards models were used to estimate cause-specific hazard ratios.

    The presentation describes the study as large and observational but does not mention the propensity-score matching or Cox time-to-event modeling used in the paper.

    From Retrospective population-based cohort; time-dependent propensity score matched analysis; Cox cause-specific hazards

  • Matched cohort sizes: 10,833 NBP-vs-untreated matched pairs and 3,080 NBP-vs-non-NBP matched pairs.

    The story reports the overall sample size of 121,492 but does not report the matched-pair sample sizes from which the key hazard-ratio comparisons were estimated.

    From Retrospective population-based cohort; time-dependent propensity score matched analysis; Cox cause-specific hazards

  • Secondary decision metrics: the paper reports absolute risk reductions of 0.007, 0.018, and 0.021 at 1, 3, and 5 years, with corresponding NNTs of 133, 56, and 48.

    The presentation focuses on relative lower-risk estimates and does not mention the paper’s absolute risk reduction or number-needed-to-treat results.

    From Secondary analytic output from time-dependent propensity-score matched observational cohorts

  • Limitation of the secondary ARR/NNT metrics: the abstract profile does not specify which comparator the ARRs/NNTs refer to or the detailed computation/handling of censoring.

    Because the story does not report the ARR/NNT metrics, it also does not discuss these abstract-level limitations of those secondary estimates.

    From Secondary analytic output from time-dependent propensity-score matched observational cohorts

7 things the story did carry across
  • Primary paper question: whether nitrogen-containing bisphosphonate use is associated with reduced Alzheimer’s disease and related dementia risk among adults aged 60+ with osteoporosis or fragility fracture in Hong Kong.
  • Study design: retrospective population-based healthcare-database cohort, i.e. observational rather than randomized or experimental.
  • Comparators: NBP users were compared with untreated patients and with users of other non-NBP anti-osteoporosis medications.
  • Main result versus untreated patients: NBP use was associated with lower ADRD incidence, HR 0.84 with 95% CI 0.78–0.90.
  • Main result versus non-NBP anti-osteoporosis medication users: NBP use was associated with lower ADRD incidence, HR 0.76 with 95% CI 0.66–0.89.
  • Interpretation limitation: estimates come from observational matched cohorts and may be affected by residual confounding rather than proving causality.
  • Paper-level recommendation: the authors suggest further study of NBPs given the observed association and potential repurposing relevance.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate whether nitrogen-containing bisphosphonate (NBP) use is associated with reduced risk of Alzheimer’s disease and related dementia (ADRD) among adults ≥60 with osteoporosis or fragility fracture in Hong Kong.Retrospective population-based cohort; time-dependent propensity score matched analysis; Cox cause-specific hazardsExpand

In plain English

Retrospective population-based cohort study of adults aged ≥60 with osteoporosis or fragility fracture in a Hong Kong healthcare database (2005–2020), comparing nitrogen-containing bisphosphonate (NBP) users to untreated patients and to users of non-NBP anti-osteoporosis medications using 1:1 time-dependent propensity score matching. Follow-up continued to December 31, 2021. In matched analyses, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia (ADRD): vs untreated HR 0.84 (95% CI 0.78–0.90) and vs non-NBPs HR 0.76 (95% CI 0.66–0.89). The authors report absolute risk reductions of 0.007, 0.018, and 0.021 at 1, 3, and 5 years (NNTs 133, 56, and 48). The manuscript concludes that NBP use was associated with lower risk of ADRD and suggests further study.

Key findings

  • In time-dependent propensity score–matched cohorts, NBP use was associated with lower incidence of Alzheimer’s disease and related dementia compared with untreated patients.HR 0.84 (95% CI 0.78–0.90)
  • In matched analyses, NBP use was associated with lower ADRD incidence compared with users of non-NBP anti-osteoporosis medications.HR 0.76 (95% CI 0.66–0.89)
“We identified patients aged 60+ with osteoporosis or fragility fracture in 2005-2020 from a healthcare database in Hong Kong.”
2secondary dataQuantify absolute risk reductions and number-needed-to-treat (NNT) over 1, 3, and 5 years for NBP use versus comparator groups.Secondary analytic output from time-dependent propensity-score matched observational cohortsExpand

In plain English

The abstract reports absolute risk reductions (ARR) of 0.007, 0.018, and 0.021 at 1, 3, and 5 years and corresponding NNTs of 133, 56, and 48 for nitrogen-containing bisphosphonate (NBP) use; these quantities are presented as derived from the matched observational cohort analyses.

Key findings

  • Abstract reports absolute risk reductions for ADRD associated with NBP use of 0.007, 0.018, and 0.021 at 1, 3, and 5 years respectively, and corresponding NNTs of 133, 56, and 48.ARR = 0.007 (1 yr); 0.018 (3 yr); 0.021 (5 yr). NNT = 133 (1 yr); 56 (3 yr); 48 (5 yr).
“NBPs resulted in an absolute risk reduction of 0.007, 0.018, and 0.021 at 1, 3, and 5 years, respectively.”
What this piece can’t prove
  • The abstract does not specify the exact comparator for the reported ARRs/NNTs (untreated vs non-NBP).
  • These metrics are derived from observational matched cohorts; potential residual confounding and censoring assumptions could affect the reported ARRs and NNTs.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

SelectedOpen access

Bisphosphonates and the risk of dementia in patients with osteoporosis or fragility fracture: A population-based study in Hong Kong.

Alzheimer's & Dementia : the Journal of the Alzheimer's Association · 2025 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Nitrogen-containing bisphosphonate was associated with a lower risk of dementia in patients with fragility fractures: A population-based cohort study in Hong Kong

Osteoporosis and Sarcopenia · 2023 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.